

# Aksam A Yassin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9610771/aksam-a-yassin-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

1,662  
citations

25  
h-index

40  
g-index

48  
ext. papers

1,848  
ext. citations

2.7  
avg, IF

4.71  
L-index

#	Paper	IF	Citations
47	Endocrine aspects of male sexual dysfunctions. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 1627-56	1.1	142
46	Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 284-93	1.1	111
45	A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. <i>Journal of Andrology</i> , <b>2008</b> , 29, 102-5		107
44	Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. <i>Journal of Sexual Medicine</i> , <b>2014</b> , 11, 1567-76	1.1	105
43	Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. <i>Aging Male</i> , <b>2016</b> , 19, 64-9	2.1	80
42	Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. <i>International Journal of Endocrinology</i> , <b>2014</b> , 2014, 683515	2.7	80
41	Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. <i>Aging Male</i> , <b>2007</b> , 10, 189-96	2.1	80
40	Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. <i>Journal of Sexual Medicine</i> , <b>2007</b> , 4, 497-501	1.1	76
39	Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 1104-1111	14.6	70
38	Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 727-735	1.1	70
37	Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. <i>Journal of Urology</i> , <b>2015</b> , 193, 80-6	2.5	65
36	An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. <i>Archives of Andrology</i> , <b>2007</b> , 53, 353-7		61
35	Lower urinary-tract symptoms and testosterone in elderly men. <i>World Journal of Urology</i> , <b>2008</b> , 26, 359-64		52
34	Testosterone and erectile dysfunction. <i>Journal of Andrology</i> , <b>2008</b> , 29, 593-604		48
33	More than eight years hands-on experience with the novel long-acting parenteral testosterone undecanoate. <i>Asian Journal of Andrology</i> , <b>2007</b> , 9, 291-7	2.8	48
32	Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. <i>World Journal of Urology</i> , <b>2014</b> , 32, 1049-54	4	38
31	Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). <i>World Journal of Urology</i> , <b>2006</b> , 24, 639-44	4	38

30	Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. <i>BJU International</i> , <b>2007</b> , 99, 988-92	5.6	36
29	Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. <i>Clinical Endocrinology</i> , <b>2016</b> , 84, 107-14	3.4	35
28	Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. <i>Aging Male</i> , <b>2015</b> , 18, 186-94	2.1	34
27	Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports. <i>Aging Male</i> , <b>2015</b> , 18, 164-8	2.1	32
26	Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men. <i>Korean Journal of Urology</i> , <b>2015</b> , 56, 310-7		31
25	Testosterone depot injection in male hypogonadism: a critical appraisal. <i>Clinical Interventions in Aging</i> , <b>2007</b> , 2, 577-90	4	31
24	Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. <i>Vascular Health and Risk Management</i> , <b>2016</b> , 12, 251-61	4.4	29
23	Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. <i>Aging Male</i> , <b>2017</b> , 20, 125-133	2.1	27
22	Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. <i>Aging Male</i> , <b>2017</b> , 20, 45-48	2.1	24
21	Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2016</b> , 14, 31-6	1.7	20
20	Sex-based differences in severity and mortality in COVID-19. <i>Reviews in Medical Virology</i> , <b>2021</b> , 31, e2223	1.7	19
19	Is there a relationship between the severity of erectile dysfunction and the comorbidity profile in men with late onset hypogonadism?. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2015</b> , 13, 162-8	1.7	15
18	The role of the urologist in the prevention and early detection of cardiovascular disease. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2011</b> , 9, 57-62	1.7	14
17	Combined testosterone and vardenafil treatment for restoring erectile function in hypogonadal patients who failed to respond to testosterone therapy alone. <i>Journal of Sexual Medicine</i> , <b>2014</b> , 11, 543-52	1.1	12
16	Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2011</b> , 9, 147-52	1.7	12
15	TESTOSTERONE TREATMENT IN HYPOGONADAL PATIENTS DOES NOT CAUSE HIGHER INCIDENCE OF PROSTATE CANCER. <i>Journal of Urology</i> , <b>2008</b> , 179, 301-301	2.5	5
14	Long-acting testosterone undecanoate for parenteral testosterone therapy. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 709-721		4
13	The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study. <i>Annals of Medicine and Surgery</i> , <b>2021</b> , 69, 102748	2	4

12	Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. <i>Aging Male</i> , <b>2020</b> , 23, 1553-1563	2.1	3
11	Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2021</b> , 19, 376-386	1.7	1
10	Copper(I)-catalyzed regioselective Ullmann-type coupling of primary carbamates and 5-substituted-1,2,3-triiodobenzenes: facile synthesis of 2,3-diiodinated N-aryl carbamates. <i>New Journal of Chemistry</i> , <b>2021</b> , 45, 8432-8439	3.6	1
9	A systematic review on the latest developments in testosterone therapy: Innovations, advances, and paradigm shifts. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2021</b> , 19, 370-375	1.7	1
8	Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data. <i>Vascular Health and Risk Management</i> , <b>2021</b> , 17, 497-508	4.4	1
7	CuI-Catalyzed Ullmann-Type Coupling of Phenols and Thiophenols with 5-Substituted 1,2,3-Triiodobenzenes: Facile Synthesis of Mammary Carcinoma Inhibitor BTO-956 in One Step. <i>Synthesis</i> , <b>2021</b> , 53, 2665-2675	2.9	0
6	HbA1c over 8.5% is not predictive of increased infection rate following penile prosthesis implant surgery in diabetic patients with erectile dysfunction. <i>Andrologia</i> , <b>2021</b> , 53, e14132	2.4	0
5	Testosterone Therapy: Injectable Androgens <b>2017</b> , 237-251		
4	Innovation in the medical treatment of advanced prostate cancer. <i>Journal of Men's Health</i> , <b>2009</b> , 6, 269-269		
3	The role for intramuscular testosterone injection in the gel era. <i>Current Sexual Health Reports</i> , <b>2007</b> , 4, 125-130	1.2	
2	Palladium-Catalyzed Regioselective Coupling of Amidines and 1,2,3-Triiodobenzenes: Facile Synthesis of 2,3-Diiodinated N-Arylbenzimidamides as Potential MDM2 and MDM4 Inhibitors. <i>ChemistrySelect</i> , <b>2021</b> , 6, 3417-3423	1.8	
1	Fatal Renal Mucormycosis in an Apparently Healthy Young Man: A Case Report With Review of Literature. <i>American Journal of Clinical Pathology</i> , <b>2018</b> , 150, S33-S34	1.9	